<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509197</url>
  </required_header>
  <id_info>
    <org_study_id>SFA110717</org_study_id>
    <nct_id>NCT00509197</nct_id>
  </id_info>
  <brief_title>Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?</brief_title>
  <official_title>Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of inhaled corticosteroids (ICS) in asthmatic subjects showing no sputum
      eosinophils is controversial. The broad aim of this study is to assess whether ICS alone or
      in combination with long-acting beta-2 agonists are an effective treatment in
      non-eosinophilic asthmatic subjects. Methods: The investigators will perform a randomized
      double-blind, placebo-controlled, multicenter study comparing the efficacy of ICS and placebo
      for 4 weeks followed by a 4-week open treatment period with ICS/salmeterol in steroid-naïve
      asthmatic subjects without sputum eosinophilia. The primary outcome will be the the Asthma
      Control Questionnaire (ACQ) score after four weeks of treatment by ICS or placebo.

      This study will determine whether or not non-eosinophilic asthmatic subjects respond to ICS
      and if they further benefit from the addition of a long-acting beta-2 agonists. This study
      will also determine whether or not the assessment of airway inflammation should be performed
      in every asthmatic patient in order to give the most appropriate treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General objective: To assess whether inhaled corticosteroids alone or in combination with
      long-acting beta-2 agonists are an effective treatment in non-eosinophilic asthmatic
      subjects.

      Specific objective 1. To compare the change in clinical and functional outcomes after
      treatment with fluticasone or placebo in non-eosinophilic asthmatic subjects.

      Specific objective 2. To assess whether the combination of inhaled corticosteroids (ICS) and
      with long-acting beta-2 agonists provides an improvement of asthma control compared to the
      treatment with ICS or placebo in non-eosinophilic asthmatics.

      Hypothesis: Treatment with ICS induces a significant clinical and physiologic improvement of
      non-eosinophilic asthmatic subjects. ICS/Salmeterol also provides a clinical and physiologic
      benefit compared to placebo.

      Primary end point: Asthma Control Questionnaire (ACQ) score after 4 weeks of treatment with
      ICS or placebo.

      The Asthma Control Questionnaire has been chosen as a primary outcome since it is the most
      relevant clinical measure to assess asthma control over a short period of time. In patients
      whose asthma is stable between clinic visits, reliability of the ACQ is high (intraclass
      correlation coefficient (ICC)=0.90). Furthermore, the questionnaire is also very responsive
      to changes in asthma control(7). Therefore, this is the ideal tool to assess and compare the
      changes in asthma control over a short period of time. This instrument has the advantage of
      including both asthma symptoms as well as forced expiratory flow in one second (FEV1). A
      change of ACQ of 0.5 has been shown to be clinically significant. Therefore, we will be able
      to assess whether or not a treatment with ICS has the ability to significantly improve asthma
      control in non-eosinophilic asthmatic subjects. The questionnaire is provided in appendix
      III. Other functional and clinical outcomes such as quality of life, FEV1, provocative
      concentration of methacholine inducing a 20% fall in FEV1 (PC20), number of rescue medication
      and number of asthma exacerbations will also be assessed as secondary outcomes.

      The study has two steps: The first step will be a randomized double-blind,
      placebo-controlled, multicenter study comparing the efficacy of ICS and placebo for 4 weeks
      in asthmatic subjects without sputum eosinophilia followed by an open ICS/salmeterol 4-week
      treatment for all subjects. (See study design in appendix III).

      Inclusion criteria One hundred subjects will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to complete the recruitment.
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Control Questionnaire (ACQ) Score After 4 Weeks of Treatment With Inhaled Corticosteroids (ICS) or Placebo</measure>
    <time_frame>Four weeks</time_frame>
    <description>Validated questionnaire assessing asthma control after 4 weeks of treatment with ICS or placebo. The ACQ has 7 questions (the top scoring 5 symptoms, FEV1% pred. and daily rescue bronchodilator use). Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom and bronchodilator use questions on a 7-point scale (0=no impairment, 6= maximum impairment). The ACQ score is the mean of 7 items and thus ranges between 0 (well controlled) and 6 (extremely poorly controlled) to yield a mean score out of 6. The higher the score, the worst asthma control is.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life Questionnaire (AQLQ) Score After 4 Weeks of Treatment</measure>
    <time_frame>Four weeks</time_frame>
    <description>Validated questionnaire assessing quality of life related to asthma after 4 weeks of treatment. The AQLQ is composed of 32 questions in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The AQLQ score is rated on a 7-point scale (1=maximal impairment, 7=no impairment) to yield a mean score out of 7. The worse the quality of life is , the lower the score is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Four weeks</time_frame>
    <description>Change in forced expiratory volume in one second (FEV1) after fluticasone or placebo treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Provocative Concentration of Methacholine Inducing a 20% Fall in FEV1 (PC20)</measure>
    <time_frame>Four weeks</time_frame>
    <description>Change in provocative concentration of methacholine inducing a 20% fall in FEV1 (PC20) after fluticasone or placebo treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Active treatment group (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention : treatment with inhaled corticosteroids (Fluticasone) will be administered to this group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group treated with placebo (B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>treatment with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (sham inhaler)</intervention_name>
    <arm_group_label>Control group treated with placebo (B)</arm_group_label>
    <other_name>Sham inhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>Fluticasone 250mcg bid for one month</description>
    <arm_group_label>Active treatment group (A)</arm_group_label>
    <other_name>Flovent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are between 18 and 70 years of age at the time of signing the informed consent.

          -  Have a diagnosis of asthma according to the Guidelines for the Diagnosis and
             Management of Asthma and have not been treated with ICS in the previous two months.

          -  Have a PC20 methacholine less than 8 mg/ml.

          -  Have a baseline FEV1 greater or equal to 65% of predicted value (at least 6 hours
             after bronchodilator).

          -  Are not optimally controlled with short-acting 2 agonists as shown by awakenings due
             to asthmatic symptoms at least once a week, or regular use of salbutamol on 4 or more
             occasions per week (excluding exercise prophylaxis) due to asthma symptoms.

          -  ACQ score equal or greater than 2

          -  Have sputum eosinophils less than 2%

          -  Are non smokers or ex-smokers who smoked a maximum of 10 pack/year.

        Exclusion Criteria:

          -  Hospitalized patients within the last 3 months

          -  Current or recent (within the last month) symptoms of a cold or flu

          -  Patients with a history of near fatal asthma

          -  Subjects on inhaled corticosteroids, prednisone, long-acting beta 2 agonists,
             montelukast or theophylline, within 2 months prior to entry into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Lemiere, MD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital du Sacre-Coeur de Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Calgary University</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Firestone Institute for Respiratory Health</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Meakins-Christie Laboratories</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Coeur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2007</study_first_submitted>
  <study_first_submitted_qc>July 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <results_first_submitted>May 26, 2015</results_first_submitted>
  <results_first_submitted_qc>July 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2016</results_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Montréal</investigator_affiliation>
    <investigator_full_name>Catherine Lemiere</investigator_full_name>
    <investigator_title>MD,MSc</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Non-eosinophilic Asthma</keyword>
  <keyword>sputum eosinophils</keyword>
  <keyword>Inhaled Corticosteroids</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone 500 mcg Bid</title>
          <description>Treatment with Inhaled Corticosteroids</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>treatment with placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone 500 mcg Bid</title>
          <description>Treatment with inhaled corticosteroids</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Treatment with placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="15.3"/>
                    <measurement group_id="B2" value="43" spread="11.7"/>
                    <measurement group_id="B3" value="40.5" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Asthma Control Questionnaire (ACQ) Score After 4 Weeks of Treatment With Inhaled Corticosteroids (ICS) or Placebo</title>
        <description>Validated questionnaire assessing asthma control after 4 weeks of treatment with ICS or placebo. The ACQ has 7 questions (the top scoring 5 symptoms, FEV1% pred. and daily rescue bronchodilator use). Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom and bronchodilator use questions on a 7-point scale (0=no impairment, 6= maximum impairment). The ACQ score is the mean of 7 items and thus ranges between 0 (well controlled) and 6 (extremely poorly controlled) to yield a mean score out of 6. The higher the score, the worst asthma control is.</description>
        <time_frame>Four weeks</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>Treatment with inhaled corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Use of placebo inhaler (sham fluticasone)</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire (ACQ) Score After 4 Weeks of Treatment With Inhaled Corticosteroids (ICS) or Placebo</title>
          <description>Validated questionnaire assessing asthma control after 4 weeks of treatment with ICS or placebo. The ACQ has 7 questions (the top scoring 5 symptoms, FEV1% pred. and daily rescue bronchodilator use). Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom and bronchodilator use questions on a 7-point scale (0=no impairment, 6= maximum impairment). The ACQ score is the mean of 7 items and thus ranges between 0 (well controlled) and 6 (extremely poorly controlled) to yield a mean score out of 6. The higher the score, the worst asthma control is.</description>
          <population>Intention to treat</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.5"/>
                    <measurement group_id="O2" value="2.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Quality of Life Questionnaire (AQLQ) Score After 4 Weeks of Treatment</title>
        <description>Validated questionnaire assessing quality of life related to asthma after 4 weeks of treatment. The AQLQ is composed of 32 questions in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 ‘patient-specific’ questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The AQLQ score is rated on a 7-point scale (1=maximal impairment, 7=no impairment) to yield a mean score out of 7. The worse the quality of life is , the lower the score is.</description>
        <time_frame>Four weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>Treatment with inhaled corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Use of placebo inhaler (sham fluticasone)</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Quality of Life Questionnaire (AQLQ) Score After 4 Weeks of Treatment</title>
          <description>Validated questionnaire assessing quality of life related to asthma after 4 weeks of treatment. The AQLQ is composed of 32 questions in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 ‘patient-specific’ questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The AQLQ score is rated on a 7-point scale (1=maximal impairment, 7=no impairment) to yield a mean score out of 7. The worse the quality of life is , the lower the score is.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="1.2"/>
                    <measurement group_id="O2" value="4.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Change in forced expiratory volume in one second (FEV1) after fluticasone or placebo treatment.</description>
        <time_frame>Four weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>Treatment with Fluticasone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment with placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Change in forced expiratory volume in one second (FEV1) after fluticasone or placebo treatment.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.1"/>
                    <measurement group_id="O2" value="-0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Provocative Concentration of Methacholine Inducing a 20% Fall in FEV1 (PC20)</title>
        <description>Change in provocative concentration of methacholine inducing a 20% fall in FEV1 (PC20) after fluticasone or placebo treatment</description>
        <time_frame>Four weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone</title>
            <description>Treatment with inhaled corticosteroids</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Use of placebo inhaler (sham fluticasone)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Provocative Concentration of Methacholine Inducing a 20% Fall in FEV1 (PC20)</title>
          <description>Change in provocative concentration of methacholine inducing a 20% fall in FEV1 (PC20) after fluticasone or placebo treatment</description>
          <units>mg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.6"/>
                    <measurement group_id="O2" value="2.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone 500 mcg Bid</title>
          <description>Treatment with inhaled Corticosteroids</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Treatment with placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Very small sample size. Impossible to recruit the anticipated number of subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Catherine Lemiere</name_or_title>
      <organization>Hôpital du Sacré-Coeur de Montréal</organization>
      <phone>514 338 2796</phone>
      <email>catherine.lemiere@umontreal.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

